Under the upsurge of innovation, pharmaceutical companies are cooperating more and more frequently

In order to enhance and expand the R&D pipeline and accelerate the commercialization of products, strong cooperation between pharmaceutical companies has become very common
in the industry.
Since October, a large number of domestic and foreign pharmaceutical companies have launched a number of cooperation
in innovation.
For example, on October 11, AIDE Biotech announced that the company and its wholly-owned subsidiary, Xiamen AIDE Biotechnology Research Center Co.
, Ltd.
, recently signed a cooperation agreement
with BeiGene (Beijing) Biotechnology Co.
, Ltd.
The company's self-developed HER2 gene IHC and FISH test kits will be submitted as companion diagnostics to support the registration of BeiGene's ongoing research projects in China, contributing to the development of
precision cancer diagnosis and treatment.
AdMed Biologics said that this cooperation, its companion diagnostic solution system on the IHC and FISH platforms will empower the research and development of new drugs, and will also further expand the field of companion diagnostic indications of
AdMed Biologics.
According to the news on October 11, the signing ceremony of Merck's trademark license authorization Biowisdom Valley (Chengdu) Technology Co.
, Ltd.
and the launching ceremony of Merck's empowered composite macromolecular CDMO project was officially held
.
Through this cooperation, Merck and BioIntelligence Valley are committed to jointly building a macromolecular composite CDMO public technical service platform project
for biopharmaceutical innovation enterprises and industries in the Sichuan-Chongqing region.
The project includes public R&D platform, process development and protein characterization research laboratory, pilot plant, biomedical R&D, production technology service outsourcing business, etc
.
On October 11, Heyuan Biotechnology (Shanghai) Co.
, Ltd.
and Shanghai Weimei Gene Technology Co.
, Ltd.
officially signed a strategic cooperation agreement
.
Relying on their own technology accumulation and resource advantages, and with the help of Weimei Gene's AAVMeta vector development platform, the two parties will break the limitations of conventional serotypes in gene therapy applications, achieve innovative breakthroughs from the underlying technology, and jointly strive to improve the effectiveness, safety and clinical accessibility of gene therapy and accelerate the development of
precision gene therapy 。 On October 10, CR Pharma and Fosun Pharma jointly announced that they have reached a strategic cooperation under which the two parties will carry out comprehensive cooperation in the field of general health, focusing on innovative drugs, biological drugs, medical devices and other fields through strategic and business cooperation, and strengthen the global layout and industrialization development
of both parties in related fields 。 According to the agreement, the two parties will focus on clinical needs and cutting-edge biotechnology to accelerate the research and development and industrialization of innovative drugs and high-end medical devices in China.
At the same time, relying on CR Pharma's strong industrial precipitation and resource advantages and Fosun Pharma's strong new drug R&D and globalization capabilities, we will deepen international cooperation between the two sides and jointly expand overseas markets.
Overall, in order to strengthen and expand the R&D pipeline and accelerate the commercialization of products, strong alliances between pharmaceutical companies have become more and more common
in the industry.
Analysts believe that this is mainly due to the characteristics of large investment, high risk and many variables in innovation, and the current medical environment is in a period of change
.
In the future, in order to cope with more and more market challenges, accelerate the research and development of new drugs, develop combination therapies, and enhance competitiveness, a large number of domestic and foreign pharmaceutical companies will continue to cooperate to achieve win-win results
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.